243 related articles for article (PubMed ID: 35628700)
1. Probiotic Yeast
Abid R; Waseem H; Ali J; Ghazanfar S; Muhammad Ali G; Elasbali AM; Alharethi SH
J Fungi (Basel); 2022 Apr; 8(5):. PubMed ID: 35628700
[No Abstract] [Full Text] [Related]
2. Health-promoting properties of
Ansari F; Alian Samakkhah S; Bahadori A; Jafari SM; Ziaee M; Khodayari MT; Pourjafar H
Crit Rev Food Sci Nutr; 2023; 63(4):457-485. PubMed ID: 34254862
[No Abstract] [Full Text] [Related]
3. Effect of microencapsulation on
Ghorbani-Choboghlo H; Nikaein D; Khosravi AR; Rahmani R; Farahnejad Z
Iran J Microbiol; 2019 Apr; 11(2):160-165. PubMed ID: 31341571
[TBL] [Abstract][Full Text] [Related]
4. Antioxidant properties and global metabolite screening of the probiotic yeast Saccharomyces cerevisiae var. boulardii.
Datta S; Timson DJ; Annapure US
J Sci Food Agric; 2017 Jul; 97(9):3039-3049. PubMed ID: 27868205
[TBL] [Abstract][Full Text] [Related]
5. Transcriptome-wide differences between Saccharomyces cerevisiae and Saccharomyces cerevisiae var. boulardii: Clues on host survival and probiotic activity based on promoter sequence variability.
Pais P; Oliveira J; Almeida V; Yilmaz M; Monteiro PT; Teixeira MC
Genomics; 2021 Mar; 113(2):530-539. PubMed ID: 33482324
[TBL] [Abstract][Full Text] [Related]
6. Fungemia following Saccharomyces cerevisiae var. boulardii probiotic treatment in an elderly patient.
Landaburu MF; López Daneri GA; Relloso S; Zarlenga LJ; Vinante MA; Mujica MT
Rev Argent Microbiol; 2020; 52(1):27-30. PubMed ID: 31262611
[TBL] [Abstract][Full Text] [Related]
7. Unique genetic basis of the distinct antibiotic potency of high acetic acid production in the probiotic yeast
Offei B; Vandecruys P; De Graeve S; Foulquié-Moreno MR; Thevelein JM
Genome Res; 2019 Sep; 29(9):1478-1494. PubMed ID: 31467028
[TBL] [Abstract][Full Text] [Related]
8. Production of neoagarooligosaccharides by probiotic yeast Saccharomyces cerevisiae var. boulardii engineered as a microbial cell factory.
Jin Y; Yu S; Liu JJ; Yun EJ; Lee JW; Jin YS; Kim KH
Microb Cell Fact; 2021 Aug; 20(1):160. PubMed ID: 34407819
[TBL] [Abstract][Full Text] [Related]
9.
Pais P; Almeida V; Yılmaz M; Teixeira MC
J Fungi (Basel); 2020 Jun; 6(2):. PubMed ID: 32512834
[No Abstract] [Full Text] [Related]
10. Saccharomyces boulardii administration changes gut microbiota and reduces hepatic steatosis, low-grade inflammation, and fat mass in obese and type 2 diabetic db/db mice.
Everard A; Matamoros S; Geurts L; Delzenne NM; Cani PD
mBio; 2014 Jun; 5(3):e01011-14. PubMed ID: 24917595
[TBL] [Abstract][Full Text] [Related]
11. Microbiome Engineering Using Probiotic Yeast:
Kim J; Atkinson C; Miller MJ; Kim KH; Jin YS
Microbiol Spectr; 2023 Aug; 11(4):e0078023. PubMed ID: 37436157
[TBL] [Abstract][Full Text] [Related]
12. Unique Probiotic Properties and Bioactive Metabolites of Saccharomyces boulardii.
Fu J; Liu J; Wen X; Zhang G; Cai J; Qiao Z; An Z; Zheng J; Li L
Probiotics Antimicrob Proteins; 2023 Aug; 15(4):967-982. PubMed ID: 35608794
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders.
Kelesidis T; Pothoulakis C
Therap Adv Gastroenterol; 2012 Mar; 5(2):111-25. PubMed ID: 22423260
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the Probiotic Yeast Saccharomyces boulardii in the Healthy Mucosal Immune System.
Hudson LE; McDermott CD; Stewart TP; Hudson WH; Rios D; Fasken MB; Corbett AH; Lamb TJ
PLoS One; 2016; 11(4):e0153351. PubMed ID: 27064405
[TBL] [Abstract][Full Text] [Related]
15. β-Galactomannan and Saccharomyces cerevisiae var. boulardii modulate the immune response against Salmonella enterica serovar Typhimurium in porcine intestinal epithelial and dendritic cells.
Badia R; Brufau MT; Guerrero-Zamora AM; Lizardo R; Dobrescu I; Martin-Venegas R; Ferrer R; Salmon H; Martínez P; Brufau J
Clin Vaccine Immunol; 2012 Mar; 19(3):368-76. PubMed ID: 22301691
[TBL] [Abstract][Full Text] [Related]
16. Strain engineering and metabolic flux analysis of a probiotic yeast Saccharomyces boulardii for metabolizing L-fucose, a mammalian mucin component.
Kim J; Cheong YE; Yu S; Jin YS; Kim KH
Microb Cell Fact; 2022 Oct; 21(1):204. PubMed ID: 36207743
[TBL] [Abstract][Full Text] [Related]
17. Yeasts as probiotics: Mechanisms, outcomes, and future potential.
Sen S; Mansell TJ
Fungal Genet Biol; 2020 Apr; 137():103333. PubMed ID: 31923554
[TBL] [Abstract][Full Text] [Related]
18. Probiotic Saccharomyces cerevisiae strains as biotherapeutic tools: is there room for improvement?
Palma ML; Zamith-Miranda D; Martins FS; Bozza FA; Nimrichter L; Montero-Lomeli M; Marques ET; Douradinha B
Appl Microbiol Biotechnol; 2015 Aug; 99(16):6563-70. PubMed ID: 26142388
[TBL] [Abstract][Full Text] [Related]
19. Application of Saccharomyces cerevisiae var. boulardii in food processing: a review.
Lazo-Vélez MA; Serna-Saldívar SO; Rosales-Medina MF; Tinoco-Alvear M; Briones-García M
J Appl Microbiol; 2018 Oct; 125(4):943-951. PubMed ID: 29961970
[TBL] [Abstract][Full Text] [Related]
20. A Mutation in
Liu JJ; Zhang GC; Kong II; Yun EJ; Zheng JQ; Kweon DH; Jin YS
Appl Environ Microbiol; 2018 May; 84(10):. PubMed ID: 29523547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]